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	 Odds	Ratio	 95%	CI	-	Lower	 95%	CI	-	Upper	
Age	band	 	 	 	
0-4	 1·27	 1·24	 1·30	
5-9	 ·91	 ·88	 ·93	
10-19	 ·93	 ·92	 ·94	
20-59	(REF)	 1	 	 	
60-69	 1·37	 1·35	 1·38	
70-79	 1·57	 1·55	 1·58	
80+	 1·67	 1·66	 1·69	
Gender	 	 	 	
Male	(REF)	 1	 	 	
Female	 1·04	 1·03	 1·04	
Diagnostic	category	 	 	 	
No	SSTI	code	(REF)	 1	 	 	
Cellulitis	or	abscess	 1·32	 1·31	 1·34	
Impetigo	 1·08	 1·06	 1·10	
Boils	/	folliculitis	 ·90	 ·89	 ·91	










Non-specific	SSTI	 ·95	 ·94	 ·96	
Other	skin	infection	 ·99	 ·96	 1·01	
No	code	 1·28	 1·27	 1·30	
Dose	 	 	 	
500mg	tablets	 1·29	 1·27	 1·31	
250mg	tablets	(REF)	 1	 	 	
Suspension	 1·00	 ·97	 1·02	
	 	 	 	




500mg	 1·00	 1·00	 1·00	
250mg	(REF)	 1	 	 	
Liquid	 1·01	 1·00	 1·01	
	 	 	 	
Constant	 ·17	 ·15	 ·16	
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